← Back to Clinical Trials
Recruiting NCT05692830

NCT05692830 Towards a Wearable Alcohol Biosensor: Examining the Accuracy of BAC Estimates From New-Generation Transdermal Technology Using Large-Scale Human Testing and Machine Learning Algorithms

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05692830
Status Recruiting
Phase
Sponsor University of Illinois at Urbana-Champaign
Condition Alcohol Drinking
Study Type OBSERVATIONAL
Enrollment 240 participants
Start Date 2022-10-22
Primary Completion 2026-08-01

Eligibility & Interventions

Sex All sexes
Min Age 21 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Alcohol

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 240 participants in total. It began in 2022-10-22 with a primary completion date of 2026-08-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The study will employ a combined laboratory-ambulatory design. Participants will engage in ambulatory assessment over the course of 14 days, wearing biosensors assessing transdermal alcohol concentration (TAC) and providing breathalyzer readings in real-world contexts. Also during this period, participants will attend three laboratory alcohol-administration sessions scheduled at one-week intervals, with alcohol dose and rate of consumption manipulated within and between participants, respectively. Laboratory visits will also double as ambulatory orientation, check-in, and close-out sessions.

Eligibility Criteria

Inclusion Criteria: * 21 years or older * drink alcohol at least 2x weekly Exclusion Criteria: * psychological or medical conditions that might contraindicate alcohol-administration * history of adverse reaction to type and amount of beverage used in the study * currently seeking treatment for alcohol use disorder * does not drink alcohol regularly * taking drugs or medications for which alcohol consumption would be contraindicated * women who are pregnant or are attempting to become pregnant

Contact & Investigator

Central Contact

Catharine Fairbairn, PhD

✉ uiucalcohollab@gmail.com

📞 217-300-5850

Principal Investigator

Catharine Fairbairn, PhD

PRINCIPAL INVESTIGATOR

University of Illinois Urbana-Champaign

Frequently Asked Questions

Who can join the NCT05692830 clinical trial?

This trial is open to participants of all sexes, aged 21 Years or older, studying Alcohol Drinking. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05692830 currently recruiting?

Yes, NCT05692830 is actively recruiting participants. Contact the research team at uiucalcohollab@gmail.com for enrollment information.

Where is the NCT05692830 trial being conducted?

This trial is being conducted at Champaign, United States.

Who is sponsoring the NCT05692830 clinical trial?

NCT05692830 is sponsored by University of Illinois at Urbana-Champaign. The principal investigator is Catharine Fairbairn, PhD at University of Illinois Urbana-Champaign. The trial plans to enroll 240 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology